Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Factors to consider when treating AML and the importance of communicating with patients

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares his opinion on the goal of treatment in acute myeloid leukemia (AML), highlighting factors to consider when treating patients, and the importance of discussing and communicating with patients to better understand what is best. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.